392 related articles for article (PubMed ID: 28348045)
1. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers.
Knudsen ES; Vail P; Balaji U; Ngo H; Botros IW; Makarov V; Riaz N; Balachandran V; Leach S; Thompson DM; Chan TA; Witkiewicz AK
Clin Cancer Res; 2017 Aug; 23(15):4429-4440. PubMed ID: 28348045
[No Abstract] [Full Text] [Related]
2. Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease.
Hutcheson J; Balaji U; Porembka MR; Wachsmann MB; McCue PA; Knudsen ES; Witkiewicz AK
Clin Cancer Res; 2016 Jul; 22(14):3606-17. PubMed ID: 26858311
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
[TBL] [Abstract][Full Text] [Related]
4. Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.
McGuigan AJ; Coleman HG; McCain RS; Kelly PJ; Johnston DI; Taylor MA; Turkington RC
J Pathol Clin Res; 2021 Mar; 7(2):99-112. PubMed ID: 33481339
[TBL] [Abstract][Full Text] [Related]
5. The Importance of a Conjoint Analysis of Tumor-Associated Macrophages and Immune Checkpoints in Pancreatic Cancer.
Xu JY; Wang WS; Zhou J; Liu CY; Shi JL; Lu PH; Ding JL
Pancreas; 2019 Aug; 48(7):904-912. PubMed ID: 31268976
[TBL] [Abstract][Full Text] [Related]
6. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.
Connor AA; Denroche RE; Jang GH; Timms L; Kalimuthu SN; Selander I; McPherson T; Wilson GW; Chan-Seng-Yue MA; Borozan I; Ferretti V; Grant RC; Lungu IM; Costello E; Greenhalf W; Palmer D; Ghaneh P; Neoptolemos JP; Buchler M; Petersen G; Thayer S; Hollingsworth MA; Sherker A; Durocher D; Dhani N; Hedley D; Serra S; Pollett A; Roehrl MHA; Bavi P; Bartlett JMS; Cleary S; Wilson JM; Alexandrov LB; Moore M; Wouters BG; McPherson JD; Notta F; Stein LD; Gallinger S
JAMA Oncol; 2017 Jun; 3(6):774-783. PubMed ID: 27768182
[TBL] [Abstract][Full Text] [Related]
7. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
8. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.
Danilova L; Ho WJ; Zhu Q; Vithayathil T; De Jesus-Acosta A; Azad NS; Laheru DA; Fertig EJ; Anders R; Jaffee EM; Yarchoan M
Cancer Immunol Res; 2019 Jun; 7(6):886-895. PubMed ID: 31043417
[TBL] [Abstract][Full Text] [Related]
9. CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer.
Shi J; Lu P; Shen W; He R; Yang MW; Fang Y; Sun YW; Niu N; Xue J
Cancer Lett; 2019 Jul; 453():158-169. PubMed ID: 30954649
[TBL] [Abstract][Full Text] [Related]
10. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma.
Liu H; Naxerova K; Pinter M; Incio J; Lee H; Shigeta K; Ho WW; Crain JA; Jacobson A; Michelakos T; Dias-Santos D; Zanconato A; Hong TS; Clark JW; Murphy JE; Ryan DP; Deshpande V; Lillemoe KD; Fernandez-Del Castillo C; Downes M; Evans RM; Michaelson J; Ferrone CR; Boucher Y; Jain RK
Clin Cancer Res; 2017 Oct; 23(19):5959-5969. PubMed ID: 28600474
[No Abstract] [Full Text] [Related]
11. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.
Helm O; Mennrich R; Petrick D; Goebel L; Freitag-Wolf S; Röder C; Kalthoff H; Röcken C; Sipos B; Kabelitz D; Schäfer H; Oberg HH; Wesch D; Sebens S
PLoS One; 2014; 9(5):e94357. PubMed ID: 24797069
[TBL] [Abstract][Full Text] [Related]
12. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
13. PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications.
Luchini C; Cros J; Pea A; Pilati C; Veronese N; Rusev B; Capelli P; Mafficini A; Nottegar A; Brosens LAA; Noë M; Offerhaus GJA; Chianchiano P; Riva G; Piccoli P; Parolini C; Malleo G; Lawlor RT; Corbo V; Sperandio N; Barbareschi M; Fassan M; Cheng L; Wood LD; Scarpa A
Hum Pathol; 2018 Nov; 81():157-165. PubMed ID: 30031096
[TBL] [Abstract][Full Text] [Related]
14. Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification.
Chen Y; Chen D; Wang Q; Xu Y; Huang X; Haglund F; Su H
Front Immunol; 2021; 12():719105. PubMed ID: 35111149
[TBL] [Abstract][Full Text] [Related]
15. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis.
Yang B; Zhou M; Wu Y; Ma Y; Tan Q; Yuan W; Ma J
Front Immunol; 2021; 12():769047. PubMed ID: 34777388
[TBL] [Abstract][Full Text] [Related]
17. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
Front Immunol; 2021; 12():643529. PubMed ID: 33679807
[No Abstract] [Full Text] [Related]
18. CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma.
Cannon A; Thompson CM; Maurer HC; Atri P; Bhatia R; West S; Ghersi D; Olive KP; Kumar S; Batra SK
Clin Cancer Res; 2020 Nov; 26(22):6051-6063. PubMed ID: 32873571
[TBL] [Abstract][Full Text] [Related]
19. IL2RA is a prognostic indicator and correlated with immune characteristics of pancreatic ductal adenocarcinoma.
Fan L; Wang X; Chang Q; Wang Y; Yang W; Liu L
Medicine (Baltimore); 2022 Oct; 101(42):e30966. PubMed ID: 36281157
[TBL] [Abstract][Full Text] [Related]
20. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma.
Mahajan UM; Langhoff E; Goni E; Costello E; Greenhalf W; Halloran C; Ormanns S; Kruger S; Boeck S; Ribback S; Beyer G; Dombroswki F; Weiss FU; Neoptolemos JP; Werner J; D'Haese JG; Bazhin A; Peterhansl J; Pichlmeier S; Büchler MW; Kleeff J; Ganeh P; Sendler M; Palmer DH; Kohlmann T; Rad R; Regel I; Lerch MM; Mayerle J
Gastroenterology; 2018 Nov; 155(5):1625-1639.e2. PubMed ID: 30092175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
